Steatohepatitis

A simple plasma-based biomarker could predict liver fibrosis in Latino adolescents with obesity

Researchers discovered a novel combination of plasma-based biomarkers that can predict liver fibrosis in Latino adolescents with obesity. The study found that dihydroxyacetone phosphate (DHAP) and alanine transaminase (ALT) were significantly associated with fibrosis, suggesting a potential low-cost, noninvasive screening tool.

SourceChildren's Hospital Los Angeles·JournalJournal of Pediatric Gastroenterology and Nutrition·TypeExperimental study·DateDec 16, 2024

Current status of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: A clinical perspective

GLP-1RAs improve liver histology, reduce liver fat, and enhance metabolic parameters in MASLD patients. However, challenges remain in assessing long-term liver benefits and clarifying the effects on liver fibrosis.

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Hepatology·DateDec 10, 2024

MASH discovery redefines subtypes with distinct risks: shaping the future of fatty liver disease treatment

A new study has identified two distinct subtypes of metabolic dysfunction-associated steatotic liver disease (MASH) with similar histological features but different clinical outcomes. The research empowers clinicians to adopt subtype-specific treatments leveraging simple clinical markers, offering a clear path to improve patient outcomes.

SourceINSERM (Institut national de la santé et de la recherche médicale)·JournalNature Medicine·DateDec 9, 2024

Broken sleep a hallmark sign of living with the most common liver disease, scientists find

A new study proves a suspected link between poor sleep and MASLD, a liver disorder that affects 30% of adults. Patients with MASLD experience significant sleep fragmentation, waking up 55% more often at night.

SourceFrontiers·JournalFrontiers in Network Physiology·TypeExperimental study·DateDec 4, 2024

Apple iPhone 17 Pro

Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.

AI finds undiagnosed liver disease in early stages

A new study reveals that an AI algorithm can accurately detect early-stage metabolic-associated steatotic liver disease (MASLD) in patients who meet the criteria, leaving 83% undiagnosed. This highlights the need for improved screening and diagnosis methods to prevent progression to advanced liver disease.

SourceAmerican Association for the Study of Liver Diseases·DateNov 16, 2024

Decoding 17-beta-hydroxysteroid dehydrogenase 13: A multifaceted perspective on its role in hepatic steatosis and associated disorders

The 17-beta-hydroxysteroid dehydrogenase 13 gene plays a significant role in regulating liver lipid metabolism, with loss-of-function variants linked to reduced risk of chronic liver disease progression. HSD17B13 modulation may provide therapeutic benefits for individuals with metabolic liver disease.

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Hepatology·DateNov 8, 2024

Advanced liver fibrosis predicts liver outcomes in biopsy-proven metabolic dysfunction-associated steatotic liver disease

A U.S.-based single-center retrospective cohort study found that advanced liver fibrosis is a primary risk factor for incident liver decompensation and liver-related events in patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease. The study, published in the Journal of Clinical and Translational Hepatolog...

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Hepatology·DateOct 25, 2024

Transcriptomic landscape analysis reveals a persistent DNA damage response in metabolic dysfunction-associated steatohepatitis post-dietary intervention

Metabolic dysfunction-associated steatohepatitis (MASLD) exhibits persistent activation of the DNA damage response (DDR) and its primary transcription factor P53 even after dietary reversal. Elevated P53 levels correlate with hepatocyte ballooning, suggesting a link between DDR signaling and MASLD recurrence.

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Hepatology·DateOct 24, 2024

A novel approach to combat fatty liver disease

Researchers found inhibiting ACMSD increases NAD+ levels, reducing inflammation and fibrosis in mouse models of MASLD/MASH. Boosting NAD+ production could protect against severe liver damage and cirrhosis.

SourceEcole Polytechnique Fédérale de Lausanne·JournalJournal of Hepatology·DateOct 9, 2024

DJI Air 3 (RC-N2)

DJI Air 3 (RC-N2) captures 4K mapping passes and environmental surveys with dual cameras, long flight time, and omnidirectional obstacle sensing.

Pipeline of new drug treatment for non-alcoholic fatty liver disease/metabolic dysfunction-associated steatotic liver disease

Researchers explore antidiabetic agents, PPAR agonists, FXR agonists, and other novel compounds to target MASLD pathogenesis. Combination therapies may enhance therapeutic efficacy while minimizing side effects, offering new hope to patients at risk of advanced liver disease.

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Hepatology·DateSep 25, 2024